Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

231
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
231
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

322
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
322
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

190
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
190
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

311
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
311
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

29
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
29
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

421
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
421

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Scoping review of community-wide screening to break the chain of TB transmission.

IJTLD open·2026
Same author

Quality of life outcomes and patient-reported experiences in a randomised controlled trial for rifampicin-resistant TB (PRACTECAL-PRO): a mixed-methods study.

IJTLD open·2026
Same author

Bedaquiline and levofloxacin replacing rifampicin for the treatment of TB.

IJTLD open·2025
Same author

Assessing the impact of the TB response in Taiwan - the journey towards ending TB.

IJTLD open·2025
Same author

Long-term efficacy and safety of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): extended follow-up of an open-label, multicentre, randomised, non-inferiority trial.

The Lancet. Respiratory medicine·2024
Same author

A survey of the effectiveness of centralized consilia in providing advice on drug-resistant TB.

IJTLD open·2024
Same journal

Rifamycin-based regimens for preventive treatment in low TB incidence countries.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2026
Same journal

The Kochi Declaration 2024 - A catalyst for global TB elimination through private sector engagement.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2026
Same journal

Preventing lung function decline and pleural thickening after pleural TB: a systematic review.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2026
Same journal

Aircraft contact investigations for TB on domestic and inbound flights to the United States.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2026
Same journal

Treatment outcome of extracorporeal membrane oxygenation in critically ill patients with pulmonary TB.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2026
Same journal

Factors associated with sputum culture positivity of <i>Mycobacterium tuberculosis</i>.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2026
See all related articles

Related Experiment Video

Updated: Sep 3, 2025

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

8.7K

Failure or relapse predictors for the STREAM Stage 1 short regimen for RR-TB.

D M Kokebu1, S Ahmed2, R Moodliar3

  • 1St Peter´s Tuberculosis Specialised Hospital/Global Health Committee, Addis Ababa, Ethiopia.

The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease
|July 28, 2022
PubMed
Summary
This summary is machine-generated.

Factors like male sex, severe TB symptoms, HIV, and costophrenic obliteration increase failure or relapse risk in multidrug-resistant TB patients on short regimens. Understanding these predictors optimizes treatment.

More Related Videos

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

7.9K
A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

10.8K

Related Experiment Videos

Last Updated: Sep 3, 2025

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

8.7K
A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

7.9K
A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

10.8K

Area of Science:

  • Infectious Diseases
  • Pulmonology
  • Public Health

Background:

  • The Standardised Treatment Regimens of Anti-tuberculosis drugs for Multidrug-Resistant Tuberculosis (STREAM) Stage 1 trial confirmed a short regimen's non-inferior efficacy for rifampicin-resistant TB (RR-TB).
  • This analysis focuses on identifying factors associated with treatment failure or relapse (FoR) in patients receiving the short regimen.

Purpose of the Study:

  • To identify baseline and early treatment factors associated with definite or probable failure or relapse (FoR) in participants receiving the short regimen for RR-TB.
  • To inform the selection of optimal shortened treatment regimens by understanding predictors of treatment outcomes.

Main Methods:

  • Analysis of 253 participants allocated to the Short regimen within the STREAM Stage 1 trial, using the modified intention-to-treat (mITT) population.
  • Multivariable Cox regression models were employed with backwards elimination to identify independent predictors of FoR events.
  • Exploration of baseline factors, Week 8 culture positivity, and Week 16 smear positivity in separate models.

Main Results:

  • Four baseline factors significantly predicted FoR: male sex, heavily positive baseline smear grade, HIV co-infection, and costophrenic obliteration.
  • Early treatment indicators also associated with FoR included culture positivity at Week 8 and smear positivity at Week 16.
  • Additional factors associated with FoR were the presence of diabetes and smoking.

Conclusions:

  • Male sex, advanced disease at baseline (high smear grade, costophrenic obliteration), and HIV co-infection are significant predictors of treatment failure or relapse in RR-TB patients on short regimens.
  • Early microbiological evidence of treatment response (negative cultures/smears) is crucial for predicting successful outcomes.
  • Comorbidities like diabetes and lifestyle factors such as smoking also influence treatment success, necessitating personalized treatment strategies.